Aptose Biosciences (APTO) Announces Formal Response to Clinical Hold for APTO-253
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Aptose Biosciences Inc. (NASDAQ: APTO) announced today that it has submitted a formal response to the U.S. Food and Drug Administration (FDA) regarding the previously announced clinical hold of Aptose’s Phase 1b clinical trial of APTO-253 in patients with hematologic cancers. Aptose provided responses to all of the questions cited in the clinical hold letter issued by the FDA.
“This submission represents months of disciplined labor to resolve a manufacturing matter related to APTO-253 that arose during our Phase 1b Trial in patients with AML and high-risk MDS,” commented Dr. William G. Rice, Chairman, President and Chief Executive Officer. “Although the FDA will make the ultimate decision whether our clinical trial may resume, all of their questions have been addressed.”
During a Phase 1b clinical trial with APTO-253, a clinical site experienced stoppage of the infusion pump during an IV infusion caused by back pressure as a result of clogging of the in-line filter. The Company determined the root cause was a chemistry-based issue with the molecule, and the Company is now working with a drug product that does not cause filter clogging or pump stoppage during mock infusion studies performed to confirm the acceptability of the updated product through the clinical infusion procedures. Such improvements to the APTO-253 manufacturing process required to address the filter clogging event will be incorporated into a Chemistry, Manufacturing and Control (CMC) amendment to our Investigational New Drug application.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Global Blood Therapeutics (GBT) Says First Patient Enrolled in Phase 3 HOPE Study in Sickle Cell Disease
- Apricus Biosciences (APRI) Vitaros Approved in Mexico for Erectile Dysfunction
- Jazz Pharmaceuticals (JAZZ) Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for Prevention of VOD
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!